Publication Name	World Journal of Hepatology
Manuscript ID	97295
Country	Italy

Received	2024-05-27 16:35
Peer-Review Started	2024-05-27 16:35
To Make the First Decision
Return for Revision	2024-09-18 04:05
Revised	2024-10-01 16:48
Second Decision	2024-10-23 02:40
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-10-23 11:41
Articles in Press	2024-10-23 11:41
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-10-28 05:36
Publish the Manuscript Online	2024-11-06 09:51

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Letter to the Editor
Article Title	Rifaximin discontinuation during broad-spectrum antibiotic treatment in critically ill patients with hepatic encephalopathy
Manuscript Source	Invited Manuscript
All Author List	Lorenzo Ridola and Alessandro Mari
ORCID	Author(s) ORCID Number Lorenzo Ridola http://orcid.org/0000-0002-8596-2609
Funding Agency and Grant Number
Corresponding Author	Lorenzo Ridola, PhD, Associate Professor, Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Viale dell'Università 37, Rome 00185, Italy. lorenzo.ridola@uniroma1.it
Key Words	Hepatic encephalopathy; Rifaximin discontinuation; Broad-spectrum antibiotics; Critically ill patients; Intensive care unit
Core Tip	According to the current international guidelines, rifaximin administration is recommended only for the secondary prophylaxis of recurrent hepatic encephalopathy (HE). The rifaximin role for the treatment of an overt HE episode in inpatients is still unclear. However, in clinical practice, it is common to keep on rifaximin therapy that patients were already on prior to hospitalization during an overt HE episode. The Ward et al study demonstrated for the first time the feasibility and safety of rifaximin discontinuation during broad-spectrum antibiotic therapy, with significant cost saving during hospitalization.
Publish Date	2024-11-06 09:51
Citation	<p>Ridola L, Mari A. Rifaximin discontinuation during broad-spectrum antibiotic treatment in critically ill patients with hepatic encephalopathy. <i>World J Hepatol</i> 2024; 16(11): 1356-1360</p>
URL	https://www.wjgnet.com/1948-5182/full/v16/i11/1356.htm
DOI	https://dx.doi.org/10.4254/wjh.v16.i11.1356

Full Article (PDF)	WJH-16-1356-with-cover.pdf
Manuscript File	97295_Auto_Edited_054823.docx
Answering Reviewers	97295-answering-reviewers.pdf
Audio Core Tip	97295-audio.wav
Conflict-of-Interest Disclosure Form	97295-conflict-of-interest-statement.pdf
Copyright License Agreement	97295-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	97295-non-native-speakers.pdf
Peer-review Report	97295-peer-reviews.pdf
Scientific Misconduct Check	97295-scientific-misconduct-check.png
Scientific Editor Work List	97295-scientific-editor-work-list.pdf
CrossCheck Report	97295-crosscheck-report.pdf